Trials / Completed
CompletedNCT01715441
Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
A Randomized Phase II Trial Assessing Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors After Failure of All Drugs Known to be Effective
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 173 (actual)
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this multicenter randomized phase II trial is to determine the efficacy of sorafenib and irinotecan combination versus irinotecan monotherapy or versus sorafenib monotherapy in metastatic colorectal cancer patients with KRAS mutated tumors after failure of all active drugs known to be effective.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib and irinotecan combination | |
| DRUG | Sorafenib monotherapy | |
| DRUG | Irinotecan monotherapy |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2015-03-01
- Completion
- 2015-09-01
- First posted
- 2012-10-29
- Last updated
- 2026-02-05
Locations
9 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01715441. Inclusion in this directory is not an endorsement.